key: cord-0726074-qf3ebsm6 authors: Bianchi, Leonardo; Biondi, Filippo; Hansel, Katharina; Murgia, Nicola; Tramontana, Marta; Stingeni, Luca title: Skin tests in urticaria/angioedema and flushing to Pfizer‐BioNTech SARS‐CoV‐2 vaccine: Limits of intradermal testing date: 2021-04-22 journal: Allergy DOI: 10.1111/all.14839 sha: c5bf4969612ba467ef2e3f14bb9462b5314028ec doc_id: 726074 cord_uid: qf3ebsm6 nan To the Editor, Table 1 . These patients underwent an allergologic workup with Pfizer-BioNTech vaccine as suggested by EAACI 4 and German allergy centres. 5 In absence of standardized methodology for this vaccine testing, we referred to Italian 6 and EAACI recommendations. 7 Unusable vaccine residues, regain from the vaccine campaign, were Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine -United States Excipients as potential agents of anaphylaxis in vaccines: analyzing the formulations of the current authorized COVID-19 vaccines EAACI statement on the diagnosis, management and prevention of severe allergic reactions to COVID-19 vaccines Practical recommendations for the allergological risk assessment of the COVID-19 vaccination -a harmonized statement of allergy centers in Germany Skin tests in the diagnosis of adverse drug reactions Skin test concentrations for systemically administered drugs -an ENDA/EAACI Drug Allergy Interest Group position paper